Send this resource to your team or professional network.
Tirzepatide Canada researchers studying GLP-1 vs GIP mechanisms should review the landmark SURMOUNT-1 tirzepatide trial (NEJM 2022) alongside SUSTAIN-7 semaglutide head-to-head data before comparing tirzepatide Canada availability to semaglutide options.
Tirzepatide Canada: GIP and GLP-1 Dual Agonism Explained
Semaglutide, tirzepatide, and retatrutide are three GLP-1 class peptides at different stages of development and approval. This comparison covers their receptor targets, mechanism differences, clinical trial efficacy data, approval status in Canada, and practical differences in dosing — with direct references to the trials that generate each figure.
How Semaglutide, Tirzepatide, and Retatrutide Differ Mechanically
The three compounds share GLP-1 receptor agonism but differ in the additional receptors they target:
| Compound | Receptor Targets | Amino Acids | Half-Life | Canada Approval |
|---|---|---|---|---|
| Semaglutide | GLP-1R | 31 aa | ~7 days | Approved (Ozempic/Wegovy) |
| Tirzepatide | GLP-1R + GIPR | 39 aa | ~5 days | Approved (Mounjaro) |
| Retatrutide | GLP-1R + GIPR + GCGR | 39 aa | ~6 days | Not approved (Phase III) |
GLP-1R agonism produces the core effects shared by all three: glucose-dependent insulin stimulation, glucagon suppression, gastric emptying delay, and CNS-mediated appetite reduction. The additional receptor targets explain the incremental efficacy signal across compounds.
GIP receptor (GIPR): The glucose-dependent insulinotropic polypeptide receptor amplifies insulin secretion and appears to reduce adipose tissue inflammation. Exactly how GIPR co-agonism contributes to tirzepatide’s superior weight loss vs semaglutide is still under investigation — one mechanism proposed is improved adipocyte signalling at the GIPR level that reduces lipid accumulation.[1]
Glucagon receptor (GCGR): Retatrutide adds GCGR co-agonism. Glucagon normally promotes hepatic glucose output (the opposite of what we want for diabetes), but in the context of triple agonism, GCGR activation increases energy expenditure and thermogenesis — compensating for its glucose-raising effect with greater caloric burn. This is the proposed mechanism behind retatrutide’s additional weight loss signal beyond tirzepatide.[2]
Semaglutide vs Tirzepatide: Head-to-Head Evidence
Unlike semaglutide and retatrutide, semaglutide and tirzepatide have direct head-to-head RCT data from the SURPASS-6 trial (N=338 adults with obesity, tirzepatide vs semaglutide 1.0 mg, 40 weeks). Tirzepatide at all three doses (5 mg, 10 mg, 15 mg) produced significantly greater reductions in HbA1c and body weight vs semaglutide 1.0 mg.[3]
For obesity specifically (SURMOUNT-5 trial, N=751, tirzepatide vs semaglutide 2.4 mg): tirzepatide 15 mg produced approximately 20.2% weight loss vs 13.7% for semaglutide 2.4 mg at 72 weeks — a statistically significant difference (~47% greater weight loss with tirzepatide).[4]
Semaglutide vs Retatrutide: Separate Trial Data
No head-to-head trial exists between semaglutide and retatrutide. Comparing them requires looking at separate trials with different populations and durations:
| Compound | Trial | N | Duration | Highest Dose | Mean Weight Loss |
|---|---|---|---|---|---|
| Semaglutide | STEP-1 | 1,961 | 68 weeks | 2.4 mg weekly | 14.9% |
| Tirzepatide | SURMOUNT-1 | 2,539 | 72 weeks | 15 mg weekly | 20.9% |
| Retatrutide | Phase II (Jastreboff 2023) | 338 | 48 weeks | 12 mg weekly | 24.2% |
The critical caveat on these numbers: retatrutide’s Phase II data is at 48 weeks. The STEP-1 and SURMOUNT-1 data are at 68 and 72 weeks respectively. Weight loss trajectories with GLP-1 class compounds are not linear — significant loss continues through 60–72 weeks. Retatrutide’s 48-week figure cannot be compared directly to the other trials’ 68–72 week figures. Phase III data (TRIUMPH program) is needed to make valid comparisons.
Tirzepatide vs Retatrutide: What Phase II Data Suggests
The Jastreboff 2023 Phase II retatrutide trial used a similar design to earlier tirzepatide trials. At 48 weeks, the retatrutide 12 mg arm showed a mean ~24.2% reduction; in SURMOUNT-1, tirzepatide 15 mg reached ~20.9% at 72 weeks. Part of retatrutide’s additional effect is attributed to glucagon-receptor activity, though this is an indirect comparison across separate trials.
Whether this advantage persists at 72 weeks and whether the GCGR agonism introduces additional tolerability considerations at higher doses are the key questions Phase III will answer. The adverse event profile in Phase II (nausea, vomiting, diarrhea) was consistent with GLP-1 class peptides and dose-dependent, similar to semaglutide and tirzepatide patterns.
Approval Status in Canada
As of 2026:
- Semaglutide: Approved by Health Canada as Ozempic (type 2 diabetes, up to 1.0 mg weekly injection; 3.0 mg oral) and Wegovy (obesity, 2.4 mg weekly injection). Also Rybelsus (oral, 3/7/14 mg daily).
- Tirzepatide: Approved by Health Canada as Mounjaro (type 2 diabetes, up to 15 mg weekly) and Zepbound (obesity). Availability may vary by province and pharmacy formulary.
- Retatrutide: Not approved in Canada or elsewhere. Phase III trials (TRIUMPH-1 and related) are ongoing. Research-grade retatrutide is available as a research chemical from suppliers like Anglo Peptides.
Dosing Comparison
| Compound | Starting Dose | Maximum Trial Dose | Escalation |
|---|---|---|---|
| Semaglutide (obesity) | 0.25 mg weekly | 2.4 mg weekly | Over 16–20 weeks |
| Tirzepatide (obesity) | 2.5 mg weekly | 15 mg weekly | Over 20 weeks |
| Retatrutide (Phase II) | 0.5–2 mg weekly | 12 mg weekly | Over 16–20 weeks |
Frequently Asked Questions
Which is stronger: semaglutide, tirzepatide, or retatrutide?
In terms of weight-loss efficacy from published trial data: retatrutide showed the highest mean weight loss (~24.2% at 48 weeks in Phase II), followed by tirzepatide (~20.9% at 72 weeks in SURMOUNT-1), followed by semaglutide (~14.9% at 68 weeks in STEP-1). These figures come from separate trials and cannot be compared directly. The only head-to-head trial (SURMOUNT-5) confirmed tirzepatide produces significantly more weight loss than semaglutide 2.4 mg.
Is tirzepatide better than semaglutide for weight loss?
Yes, based on head-to-head trial data. The SURMOUNT-5 trial (N=751) found tirzepatide 15 mg produced approximately 47% more weight loss than semaglutide 2.4 mg (20.2% vs 13.7%) at 72 weeks. The difference was statistically significant and was consistent across the primary and secondary endpoints.
Is retatrutide approved in Canada?
No. Retatrutide has not been approved by Health Canada or any other regulator. Phase III results are now reading out: TRIUMPH-1 (May 2026) reported 28.3% mean weight loss at 80 weeks on the 12 mg dose, and TRIUMPH-2 and TRIUMPH-3 (July 2026) reported 20.8% and 22.6% (efficacy estimand, per Eli Lilly). Lilly has said it plans to file with the FDA in Q1 2027. In Canada, retatrutide is sold only as a research-grade peptide for laboratory use.
What is the difference between GLP-1, GIP, and glucagon receptor agonism?
GLP-1R agonism stimulates glucose-dependent insulin release, suppresses glucagon, delays gastric emptying, and reduces appetite centrally. GIPR co-agonism adds enhanced insulin secretion and adipose tissue effects. GCGR agonism (retatrutide only) adds energy expenditure increase through thermogenesis — counterbalancing GCGR’s glucose-raising effect with greater caloric burn. The net result of triple agonism appears to be greater weight loss than dual or single agonism in Phase II data.
References
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3–14. PMID 30473097
- Finan B, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. PMID 24174327
- Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398(10313):1811–1824. PMID 34619105
- Wadden TA, et al. Tirzepatide vs semaglutide for overweight and obesity (SURMOUNT-5). N Engl J Med. 2025;392(10):950–961. PMID 40209010
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514–526. PMID 37385013
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. PMID 33567185
Related Research Articles
Continue your GLP-1 research: GLP-1 Receptor Agonist Complete Guide, Retatrutide Reconstitution Guide, and Cagrilintide Reconstitution Guide.
